Denali Therapeutics (DNLI) Projected to Announce Earnings on Tuesday

Denali Therapeutics (NASDAQ:DNLI) is expected to be releasing its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to post earnings of ($0.3222) per share and revenue of $12.22 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, August 6th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.17). The firm had revenue of $3.60 million during the quarter, compared to analysts’ expectations of $2.15 million. During the same period in the prior year, the company earned ($0.72) earnings per share. On average, analysts expect Denali Therapeutics to post ($2.70) EPS for the current fiscal year and ($2.45) EPS for the next fiscal year.

Denali Therapeutics Stock Performance

Shares of Denali Therapeutics stock opened at $18.94 on Monday. The company has a current ratio of 8.37, a quick ratio of 8.32 and a debt-to-equity ratio of 0.01. The business has a fifty day simple moving average of $20.64 and a two-hundred day simple moving average of $21.23. The firm has a market capitalization of $3.03 billion, a P/E ratio of -6.67 and a beta of 1.02. Denali Therapeutics has a 12 month low of $13.75 and a 12 month high of $27.30.

Insider Buying and Selling at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 2,768 shares of the firm’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $23.44, for a total value of $64,881.92. Following the completion of the transaction, the insider owned 278,995 shares in the company, valued at $6,539,642.80. This trade represents a 0.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.70% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. B. Riley Financial increased their price target on shares of Denali Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, August 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Thursday, October 15th. UBS Group upped their price target on Denali Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Robert W. Baird set a $34.00 price target on Denali Therapeutics in a research note on Friday, August 7th. Finally, JPMorgan Chase & Co. assumed coverage on Denali Therapeutics in a research report on Monday, July 13th. They set an “overweight” rating and a $29.00 price objective on the stock. Thirteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Denali Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $35.85.

About Denali Therapeutics

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.